转载请注明作者和来自新康界(XKJ0101)
4月23日,有消息报道,在签署价值43亿美元的Akorn(爱克龙药业)收购协议一年后,德国仿制药巨头Fresenius(费森尤斯卡比)打算取消这笔交易。
据悉,Fresenius取消交易是因为Akorn频频收到FDA勒令,再加上其独立调查出现了“重大...查看全文
交易者的天空2017-04-11 04:28
$爱克龙药业(AKRX)$ $美国转运交通公司(SWFT)$ $特斯拉(TSLA)$ AXON
clean pattern, clean move, should have wait longer for the pull back reshort.
L2 Offer showed a head fake on first entry, took me twice to get right. Morning emotion profit taking.
What happen when i...查看全文
交易者的天空2017-04-10 08:09
4/10 Watchlist
$爱克龙药业(AKRX)$ $Restoration Hardware(RH)$ $AKARI THERAPEUTICS PLC(AKTX)$ CARA CLNT TSLA
网页链接查看全文
张大丰医生2017-04-04 11:56
文章节选于:新康界 蔡德山《220亿美元多发性硬化症金矿,群雄逐鹿!》
近两年来,多发性硬化症(MS)治疗药物一直处于神经系统品类角逐的前沿。2016年全球七大医药市场多发性硬化症治疗药物销售额已突破了200亿美元的大关,其中进入全球TOP100畅销药有8个品牌,占据了7.17%的份额。虽然在部分...查看全文
神采的加薪小武士2017-01-09 00:41
$爱克龙药业(AKRX)$美国仿制药公司:爱克龙药业Akorn(AKRX)
摘 要
Akorn爱克龙药业公司在美国和国际上开发、生产和销售通用的品牌处方药品,以及动物和OTC消费保健产品。Akorn生产和销售专业领域的诊断和治疗药品,如眼科、风湿病、麻醉药及解毒剂等等。查看全文
$爱克龙药业(AKRX)$ 8-K Current report, items 7.01 and 9.01 Accession Number: 0001104659-20-080638 Act: 34 Size: 7 MB 网页链接
$爱克龙药业(AKRX)$ 8-K Current report, items 1.01 and 9.01 Accession Number: 0001104659-20-074460 Act: 34 Size: 614 KB 网页链接
$爱克龙药业(AKRX)$ 25-NSE Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities Accession Number: 0001354457-20-000239 Act: 34 Size: 3 KB 网页链接
$爱克龙药业(AKRX)$ 8-K Current report, items 1.01, 1.03, 3.01, 7.01, and 9.01 Accession Number: 0001104659-20-065866 Act: 34 Size: 2 MB 网页链接
$爱克龙药业(AKRX)$ 8-K Current report, items 1.01, 1.03, 2.03, 2.04, 7.01, and 9.01 Accession Number: 0001104659-20-064893 Act: 34 Size: 2 MB 网页链接
$爱克龙药业(AKRX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-20-060335 Size: 5 KB 网页链接
$爱克龙药业(AKRX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-20-060336 Size: 5 KB 网页链接
$爱克龙药业(AKRX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-20-060337 Size: 5 KB 网页链接
$爱克龙药业(AKRX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-20-060338 Size: 5 KB 网页链接
$爱克龙药业(AKRX)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001171843-20-003602 Act: 34 Size: 490 KB 网页链接